We are live on ! Find out more
PHAS

PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS

Delisted

PHAS was delisted on the 2nd of November, 2022.

Back to rankings

5 hedge funds and large institutions have $15.6K invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

87% less funds holding

Funds holding: 38 → 5 (-33)

97% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 34

100% less capital invested

Capital invested by funds: $3.89M → $15.6K (-$3.88M)

Holders
5
Holders Change
-33
Holders Change %
-86.84%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
34
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HLA
Hamilton Lane Advisors
Pennsylvania
+$5.61K

Top Sellers

Rank Fund Capital Flow
1
NMC
NEA Management Company
Maryland
-$1.17M
2
APM
Avidity Partners Management
Texas
-$768K
3
RSCM
Rock Springs Capital Management
Maryland
-$479K
4
MCM
MAI Capital Management
Ohio
-$406K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$318K
Name Holding Trade Value Shares
Change 		Change in
Stake
DCM
1
DAFNA Capital Management
California
$9.69K – – –
Acadian Asset Management
2
Acadian Asset Management
Massachusetts
$4K – – –
HLA
3
Hamilton Lane Advisors
Pennsylvania
$1K +$5.61K +34,208 New
IIA
4
IPG Investment Advisors
California
$864 – – –
Barclays
5
Barclays
United Kingdom
$6 – – –
NMC
6
NEA Management Company
Maryland
– -$1.17M -6,643,702 Closed
APM
7
Avidity Partners Management
Texas
– -$768K -4,361,365 Closed
RSCM
8
Rock Springs Capital Management
Maryland
– -$479K -2,719,074 Closed
MCM
9
MAI Capital Management
Ohio
– -$406K -2,307,534 Closed
Vanguard Group
10
Vanguard Group
Pennsylvania
– -$318K -1,808,098 Closed
JJ
11
Johnson & Johnson
New Jersey
– -$283K -1,607,044 Closed
BlackRock
12
BlackRock
New York
– -$116K -665,563 Closed
Geode Capital Management
13
Geode Capital Management
Massachusetts
– -$56K -320,642 Closed
PTP
14
Platform Technology Partners
New York
– -$41K -231,900 Closed
BCM
15
Bridgeway Capital Management
Texas
– -$35K -201,600 Closed
OIA
16
OneDigital Investment Advisors
Kansas
– -$30K -171,150 Closed
Jane Street
17
Jane Street
New York
– -$19K -110,661 Closed
Morgan Stanley
18
Morgan Stanley
New York
– -$17K -95,763 Closed
State Street
19
State Street
Massachusetts
– -$16K -91,850 Closed
SCA
20
Snowden Capital Advisors
New York
– -$10K -60,800 Closed
Northern Trust
21
Northern Trust
Illinois
– -$10K -58,119 Closed
NFC
22
Northeast Financial Consultants
Connecticut
– -$7K -37,760 Closed
UBV
23
United Bank (Virginia)
Virginia
– -$7K -37,400 Closed
William Blair & Company
24
William Blair & Company
Illinois
– -$6K -35,696 Closed
RJA
25
Raymond James & Associates
Florida
– -$3K -15,500 Closed
1
2

PHAS Hedge Fund Activity: Q4 2022 in Review

5 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) for Q4 2022, worth a combined $15.6K — down 100% from $3.89M a quarter earlier.

Sellers outnumbered buyers: 34 funds closed out of PHAS and 1 opened new positions — a net loss of 33 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was Hamilton Lane Advisors, opening a new position worth an estimated $5.61K. The largest seller was NEA Management Company, exiting entirely with an estimated $1.17M sold.

  • 5 institutional investors held PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) as of Q4 2022, down from 38 in Q3 2022.
  • Funds reported $15.6K of PhaseBio Pharmaceuticals, Inc. Common Stock stock for Q4 2022, down 100% quarter-over-quarter.
  • 1 fund opened new PhaseBio Pharmaceuticals, Inc. Common Stock positions in Q4 2022 and 34 closed out, a net change of -33 holders.
  • The largest PhaseBio Pharmaceuticals, Inc. Common Stock buyer in Q4 2022 was Hamilton Lane Advisors, an estimated $5.61K added.
  • The largest PhaseBio Pharmaceuticals, Inc. Common Stock seller in Q4 2022 was NEA Management Company, an estimated $1.17M sold.

Based on aggregated 13F filings for Q4 2022.